Explorer les evidences

7,4 %The frequency of COVID-19 cases was 7.4% (n = 10/135) among febrile patients screened in Gabon from October 2021 to December 2021.

GabonCOVID-19observé October 2021 to December 2021publié 2022Southern African journal of infectious diseaseseurope_pmcdocument de 4 observations

91,42 %The seroprevalence of SARS-CoV-2 antibodies in the 40-49 age group in Gabon was 91.42% (95% CI: 88.7–93.5).

GabonCOVID-19observé up to December 2021publié 2024Viruseseurope_pmcdocument de 5 observations

1 deathsAmong 92 hospitalized COVID-19 cases at the Regional Hospital of Lambaréné, there was 1 death.

GabonCOVID-19observé 2020publié 2022Medecine tropicale et sante internationalePubMeddocument de 6 observations

92 %The seroprevalence of SARS-CoV-2 antibodies in Ogoué-Lolo province, Gabon, was 92%.

GabonCOVID-19observé up to December 2021publié 2024SARS-CoV-2 Antibody Seroprevalence in Gabon: Findings from the Nationwide Household Serosueurope_pmcdocument de 6 observations

12 %12% of SARS-CoV-2 infected subjects had chronic diseases.

GabonCOVID-19publié 2021Scientific reportseurope_pmcdocument de 23 observations

18 per_1The ratio of seroprevalence from infection to cumulative incidence of confirmed cases ranged from 18:1 to 954:1 in Africa.

GabonCOVID-19publié 2022BMJ global healtheurope_pmcdocument de 4 observationsDOI 10.1136/bmjgh-2022-008793

68,3 %Among 837 patients with COVID-19 in Gabon from March to June 2020, 572 (68.3%) were men and 264 (31.5%) were women.

GabonCOVID-19observé March to June 2020publié 2021JAMA network openPubMeddocument de 10 observations

The B.1.1.7 variant of SARS-CoV-2 was detected in a hospitalized patient in Gabon in January 2021.

GabonCOVID-19observé January 2021publié 2021Journal of medical virologyeurope_pmcdocument de 2 observationsDOI 10.1002/jmv.27164

90 %The seroprevalence of SARS-CoV-2 antibodies in Estuaire province, Gabon, was 90%.

GabonCOVID-19observé up to December 2021publié 2024SARS-CoV-2 Antibody Seroprevalence in Gabon: Findings from the Nationwide Household Serosueurope_pmcdocument de 6 observations

2 %2% (N = 11) of SARS-CoV-2 infected persons had dyspnea.

GabonCOVID-19publié 2021Scientific reportseurope_pmcdocument de 23 observations

37 yearsThe median and mean ages of SARS-CoV-2 infected subjects were 37 and 38 years respectively.

GabonCOVID-19publié 2021Scientific reportseurope_pmcdocument de 23 observations

The B.1.1.7 variant of SARS-CoV-2 was introduced to Gabon in December 2020.

GabonCOVID-19observé December 2020publié 2021Journal of medical virologyeurope_pmcdocument de 2 observationsDOI 10.1002/jmv.27164

13 097 patientsA total of 13,097 COVID-19 patients sampled between mid-2021 to early 2022 from 22 African countries were tested for BA.1 by real-time RT-PCR.

GabonBA.1 · COVID-19observé mid-2021 to early 2022publié 2022Science (New York, N.Y.)europe_pmcdocument de 5 observations

69 patientsAmong 305 surveyed patients with COVID-19, 69 (23%) had renal insufficiency, which posed a risk of adverse interactions with hydroxychloroquine.

GabonCOVID-19 · renal insufficiencypublié 2021International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument de 8 observations

165 patientsAmong 305 surveyed patients with COVID-19, 165 (54%) had health conditions that did not prohibit but posed a risk of adverse interactions with hydroxychloroquine.

GabonCOVID-19publié 2021International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument de 8 observations

36,2 %The overall prevalence of anti-SARS-CoV-2 antibodies was 36.2% among 1492 enrolled people in Gabon.

GabonCOVID-19publié 2021BMC Research NotesOpenAlexdocument de 7 observationsDOI 10.1186/s13104-021-05570-3

78,3 %78.3% of COVID-19 patients were positive for anti-SARS-CoV-2 antibodies.

GabonCOVID-19publié 2021Scientific reportseurope_pmcdocument de 23 observations

24,5 %Among 809 SARS-CoV-2 samples screened by qRT-PCR in Gabon from March 2020 to September 2021, 198 (24.5%) were classified as VOC Delta (B.1.617.2).

GabonB.1.617.2 · COVID-19 · VOC Deltaobservé March 2020 to September 2021publié 2022Frontiers in medicineeurope_pmcdocument de 13 observationsDOI 10.3389/fmed.2022.877391

91,78 %The seroprevalence of SARS-CoV-2 antibodies in the 20–29 age group in Gabon was 91.78% (95% CI: 89.5–93.6).

GabonCOVID-19observé up to December 2021publié 2024SARS-CoV-2 Antibody Seroprevalence in Gabon: Findings from the Nationwide Household Serosueurope_pmcdocument de 6 observations

22,3 %After 48 hours of treatment, 50 (22.3%) patients had a significant prolongation of QTc interval.

GabonCOVID-19publié 2022Clinics and practiceeurope_pmcdocument de 5 observations

46,1 yearsPatients with severe COVID-19 symptoms had a mean age of 46.1 years (SD 14.7 years), compared to 41.3 years (SD 12.5 years) for those with mild symptoms and 35.7 years (SD 11.3 years) for those with no symptoms.

GabonCOVID-19observé March to June 2020publié 2021JAMA network openPubMeddocument de 10 observations

31 %The B.1.1.318 lineage increased by 31% in the Gabonese population between February and May 2021.

GabonB.1.1.318 lineage · COVID-19observé February and May 2021publié 2022International journal of infectious diseases : IJID : official publication of the Internateurope_pmcdocument de 2 observationsDOI 10.1016/j.ijid.2021.10.057

2,7 %2.7% (N = 16) of SARS-CoV-2 infected persons had influenza-like symptoms associated with anosmia and ageusia.

GabonCOVID-19publié 2021Scientific reportseurope_pmcdocument de 23 observations

58 patientsAmong 305 surveyed patients with COVID-19, 58 (19%) had heart failure, which posed a risk of adverse interactions with hydroxychloroquine.

GabonCOVID-19 · insuffisance cardiaquepublié 2021International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument de 8 observations

39 patientsAmong 305 surveyed patients with COVID-19, 39 (13%) had haematologic/haemato-oncologic diseases, which prohibited administration of hydroxychloroquine.

GabonCOVID-19 · haematologic/haemato-oncologic diseasespublié 2021International journal of infectious diseases : IJID : official publication of the InternatPubMeddocument de 8 observations